Italian watchdog says Novartis, Roche colluded over eye drug

Send a link to a friend  Share

[March 05, 2014]   ZURICH/MILAN (Reuters) Italy's antitrust authorities said Novartis and Roche colluded to try and stop cancer drug Avastin being used to treat a serious eye disease, and fined the Swiss drugmakers 182.5 million euros ($251 million).

In a statement on Wednesday, the Italian regulator accused the two Basel-based companies of striking an alliance to prevent distribution of Roche's Avastin as a treatment for wet age-related macular degeneration (AMD) in favor of the more expensive drug Lucentis made by Novartis.

It fined Novartis 92 million euros ($126.4 million) and Roche 90.5 million euros.

Novartis and Roche strongly denied the regulator's assertions and said they would appeal.

Although the fines are relatively small, they underline how cash-strapped governments are scrutinizing more closely the way drug companies sell their products.

The authority said it estimated that the alleged collusion has cost the Italian health service an additional 45 million euros in 2012, and said that figure could possibly exceed 600 million euros a year in the future.

Although Avastin is not licensed for AMD, it works in a similar way to Lucentis and is widely prescribed on a so-called "off label" basis. A 2011 study concluded that the drug worked as well as Lucentis in treating vision loss from AMD but that it had more adverse side effects.

Lucentis is marketed by Novartis outside of the United States and is an important drug for the company with sales of $2.38 billion last year, making it its third-biggest seller.

[to top of second column]

Sales of Lucentis for Roche, which markets the drug in the United States, were 1.69 billion Swiss francs in 2013.

($1 = 0.7277 euros)

(Reporting by Katharina Bart and Caroline Copley in Zurich and Silvia Aloisi in Milan; editing by David Holmes and Tom Pfeiffer)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top